Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.80 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.80 |
| ▸ | DRD4 | P21917 | 1/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.80 |
| ▸ | HRH2 | P25021 | 1/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.80 |
| ▸ | HRH1 | P35367 | 1/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.80 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| A-349,821 SCHEMBL7594032 | 0.89 | HRH3 (1.00) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| A-349,821 SCHEMBL15559431 | 0.89 | HRH3 (1.00) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| A-349,821 SCHEMBL29384338 | 0.89 | HRH3 (1.00) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL7599220 | 0.89 | HRH3 (0.93) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL7595727 | 0.86 | HRH3 (0.78) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL7595944 | 0.86 | HRH3 (1.00) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL7594042 | 0.83 | HRH3 (1.00) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL13328886 | 0.83 | HRH3 (1.00) | HRH3CHRM2CHRM1ADRA2CCHRM3 | |
| SCHEMBL7599582 | 0.82 | HRH3 (1.00) | HRH3 | |
| SCHEMBL14424593 | 0.80 | HPGD (0.79) | HRH3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111340-A1 | Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2002-08-15 | — | — | US | claimed |
| US-6316475-B1 | TREATMENT OF CANCER, ASTHMA, HEART DISEASES, SEIZURES, INFLAMMATION | ABBOTT LABORATORIES | 2001-11-13 | — | — | US | claimed |
| US-20020111340-A1 | Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2002-08-15 | — | — | US | disclosed |
| US-6316475-B1 | TREATMENT OF CANCER, ASTHMA, HEART DISEASES, SEIZURES, INFLAMMATION | ABBOTT LABORATORIES | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111340-A1 | Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH2 | HRH3 1/4885CHRM2 307/4885CHRM1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.